Buy Tiova Inhaler

Tiova Inhaler

What is Tiova Inhaler?

Tiova Inhaler is a prescription-only respiratory medication marketed in Hong Kong. It contains tiotropium bromide as its sole active ingredient and is supplied as a metered-dose inhaler (MDI) delivering a dose of 9 µg per actuation. Tiotropium belongs to the class of long-acting muscarinic antagonists (LAMAs) used to improve airflow in chronic lung diseases. The inhaler is intended for daily use under the supervision of a qualified healthcare professional.

How Tiova Inhaler Works in the Body

Tiotropium bromide selectively blocks muscarinic-type 3 (M₃) receptors located on airway smooth muscle. By inhibiting the action of acetylcholine, it prevents the contraction of bronchial muscles, leading to sustained bronchodilation. The drug’s high affinity for M₃ receptors and slow dissociation provide a long duration of effect, typically lasting 24 hours after a single inhalation. This mechanism reduces airway resistance, improves lung function, and helps to control symptoms such as shortness of breath and wheezing in chronic respiratory conditions.

Conditions Treated by Tiova Inhaler

Tiova Inhaler is approved by the Hong Kong Department of Health for the maintenance treatment of:

• Chronic Obstructive Pulmonary Disease (COPD) - including emphysema and chronic bronchitis components.
• Asthma - as an add-on therapy for patients whose asthma remains uncontrolled despite regular use of inhaled corticosteroids.

These indications are based on clinical trials demonstrating improved forced expiratory volume in one second (FEV₁) and reduced exacerbation rates when tiotropium is taken once daily.

Evidence-Based Off-Label Uses

Some clinical studies have explored tiotropium’s benefit in patients with chronic bronchitis without overt COPD and in severe asthma phenotypes. While these investigations suggest potential improvement in symptom control, the uses remain not approved by regulatory agencies in Hong Kong. Off-label use should only be considered after a thorough risk-benefit assessment by a specialist physician.

Who Should (Not) Use Tiova Inhaler?

Ideal Candidates

• Adults diagnosed with COPD who experience persistent dyspnea despite bronchodilator therapy.
• Adults with asthma that remains uncontrolled on inhaled corticosteroids alone.

Absolute Contraindications

• Known hypersensitivity to tiotropium bromide or any excipients of the inhaler.
• Severe hypersensitivity reactions to other anticholinergic agents.

Relative Contraindications & Precautions

• Pregnancy & lactation: Limited human data; use only if the potential benefit justifies the potential risk.
• Severe renal impairment (creatinine clearance < 30 mL/min): Dose adjustment may be required; evaluate renal function before initiating therapy.
• Narrow-angle glaucoma or urinary retention: Anticholinergic effects could exacerbate these conditions.

Patients with any of the above should discuss alternatives with their prescriber.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Dry mouth (often reported).
• Cough or throat irritation immediately after inhalation.
• Upper respiratory tract infection symptoms (e.g., mild sinus congestion).

These effects are usually mild, transient, and do not require medical intervention unless they persist.

Serious Adverse Events

• Acute urinary retention - rare but may need urgent evaluation.
• Narrow-angle glaucoma exacerbation - watch for eye pain or visual changes.
• Allergic reactions such as angioedema, rash, or anaphylaxis. Seek emergency care if these occur.

Drug Interactions

• Major: Concurrent use of other anticholinergic agents (e.g., ipratropium) may increase anticholinergic burden; monitor for dry mouth and urinary issues.
• Moderate: Strong CYP3A4 inhibitors (e.g., ketoconazole) have minimal effect because tiotropium is primarily excreted unchanged by the kidneys; still advise caution.
• Baseline advice: Always inform your healthcare provider of all prescription medicines, over-the-counter drugs, supplements, and herbal products before starting Tiova Inhaler.

Food and Lifestyle Interactions

• No significant food interactions have been identified.
• Alcohol does not affect tiotropium’s efficacy, but excessive drinking may worsen respiratory symptoms.
• Patients should avoid driving or operating machinery if they experience dizziness or severe cough after inhalation.

How to Take Tiova Inhaler

• Standard dosing: One inhalation (9 µg) once daily, preferably at the same time each day.
• Administration technique:
• Shake the inhaler gently for a few seconds.
• Exhale fully away from the device.
• Place the mouthpiece in the mouth, seal lips, and press down on the canister while inhaling slowly and deeply.
• Hold breath for about 10 seconds, then exhale slowly.
• Missed dose: If a dose is missed, take it as soon as remembered unless it is almost time for the next scheduled dose. Do not double-dose.
• Overdose: In the unlikely event of taking more than the prescribed inhalation, symptoms may include severe dry mouth, urinary retention, or paradoxical bronchospasm. Seek immediate medical attention; there is no specific antidote.
• Discontinuation: Tiova Inhaler does not require tapering. However, abrupt cessation may lead to a return of symptoms; discuss any changes with a clinician.

Monitoring and Follow-Up

• Lung function: Spirometry (FEV₁) is typically performed before initiating therapy and then at 3- to 6-month intervals to assess response.
• Exacerbation tracking: Record any worsening of breathlessness, need for rescue medication, or hospital visits.
• Renal function: Periodic serum creatinine measurement is advisable for patients with known renal impairment.
• Eye health: Patients with glaucoma should have regular ophthalmologic examinations.

Storage and Handling

• Store the inhaler at room temperature (15 °C-30 °C), protected from direct sunlight and moisture.
• Keep the canister upright to ensure proper dose delivery.
• Do not refrigerate or freeze.
• If the inhaler is damaged, leaking, or past its expiration date, discard it according to local pharmaceutical waste guidelines and obtain a replacement.

Medication-Specific Glossary

Muscarinic Receptor

A protein on airway smooth-muscle cells that binds acetylcholine, causing muscle contraction and airway narrowing.

Bronchoconstriction

The narrowing of the airways due to contraction of bronchial smooth muscle, leading to reduced airflow.

Long-acting Muscarinic Antagonist (LAMA)

A class of drugs, including tiotropium, that block muscarinic receptors for at least 24 hours, providing sustained bronchodilation.

Forced Expiratory Volume in 1 second (FEV₁)

The volume of air a person can forcefully exhale in the first second of a breath; a key measure of airway obstruction.

Renal Clearance

The process by which the kidneys eliminate a drug from the bloodstream; important for dosing tiotropium in patients with kidney disease.

Medical Disclaimer

This article provides educational information about Tiova Inhaler and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.